Impact of Chronic Hepatitis C Virus Genotype 1b Infection on Triglyceride Concentration in Serum Lipoprotein Fractions

Int J Mol Sci. 2015 Aug 31;16(9):20576-94. doi: 10.3390/ijms160920576.

Abstract

Reduced low-density lipoprotein (LDL) cholesterol level is a characteristic feature of dyslipidemia in chronic hepatitis C virus (HCV) infection. However, abnormality in serum triglyceride (TG) has not been fully investigated. To clarify the impact of HCV genotype 1b (G1b) infection and advanced fibrosis on serum TG profiles, TG concentrations in lipoprotein fractions were examined in fasting sera from 185 subjects with active or cleared HCV infection by high-performance liquid chromatography. Serum lipoproteins were fractionated into four classes: chylomicron, very low-density lipoprotein (VLDL), LDL, and high-density lipoprotein (HDL). Then, the significance of HCV G1b infection on TG levels in each lipoprotein fraction was determined using multiple regression models. We found that active HCV G1b infection was positively associated with high HDL-TG levels and low VLDL-TG levels, independent of other factors included in the regression model. In VLDL sub-fractions, active HCV infection was only found to be associated with low levels of large VLDL-TG. Similarly, advanced liver fibrosis in chronic HCV G1b infection was associated with high levels of LDL-TG, HDL-TG, and small VLDL-TG, independent of other clinical factors. These findings indicate that active HCV G1b infection and advanced fibrosis are closely associated with abnormal serum TG profiles.

Keywords: VLDL sub-fractions; chronic hepatitis C (CHC); hepatitis C virus (HCV); lipoprotein; triglyceride (TG); very-low-density lipoprotein (VLDL).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use
  • Biomarkers
  • Female
  • Genotype*
  • Hepacivirus / genetics*
  • Hepatitis C, Chronic / blood*
  • Hepatitis C, Chronic / complications
  • Hepatitis C, Chronic / drug therapy
  • Hepatitis C, Chronic / virology*
  • Humans
  • Lipoproteins / blood*
  • Lipoproteins, VLDL
  • Liver Cirrhosis / blood
  • Liver Cirrhosis / etiology
  • Liver Cirrhosis / pathology
  • Male
  • Treatment Outcome
  • Triglycerides / blood*

Substances

  • Antiviral Agents
  • Biomarkers
  • Lipoproteins
  • Lipoproteins, VLDL
  • Triglycerides
  • very low density lipoprotein triglyceride